Scarica l'app Stockscreener
31.37
7.92%
-2.70
Dopo l'orario di chiusura:
32.22
0.85
+2.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq
Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada
Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan
Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener
Japan approves new ATTR-CM treatment Beyonttra - Investing.com
Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq
Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR
Major Clinical Data Reveal: BridgeBio's ATTR-CM Treatment Shows Multiple Outcomes at ACC - Stock Titan
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN
BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN
NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights
Achondroplasia Market on Track for Major Expansion by 2034, - openPR
UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating - Marketscreener.com
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces CFO Succession - The Manila Times
BridgeBio Pharma Appoints New President and CFO - TipRanks
BridgeBio Pharma announces CFO succession -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
BridgeBio Pharma Names New CFO -March 17, 2025 at 04:21 pm EDT - Marketscreener.com
BridgeBio Promotes Internal Leader to CFO Role, Ensuring Strategic Continuity - StockTitan
BridgeBio Pharma Names Thomas Trimarch as New Finance Chief - MarketWatch
Lobbying Update: $30,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Nasdaq
BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock - Investing.com
Genetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World
Kkr sells $197.76 million in BridgeBio Pharma stock By Investing.com - Investing.com Australia
(BBIO) On The My Stocks Page - Stock Traders Daily
Major Stakeholder Sells Millions in BridgeBio Pharma Stock! - TipRanks
Kkr sells $197.76 million in BridgeBio Pharma stock - Investing.com
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):